Objective To evaluate the efficacy and safety of adjuvant therapy of prostate cancer with Chinese medicine injection. Methods Literature in CNKI

Sino Med

China science and technology journal database of Chongqing VIP Information Co.

Ltd.（ VIP）

Wangfang Data

Pub Med

Cochrane Library and Clinical Trials was retrieved up to Jan. 31 st

2016. The risk of bias of the literature screened was assessed through Cochrane Criteria

and the meta-analysis was conducted by Rev Man 5. 3 software. Results There were 14 RCTs eventually selected

including 804 patients totally. Kushen Injection（ 苦参注射液） combined with western medicine improved the quality of life significantly better than western medicine alone（ P < 0. 0001）. In each grade of National Cancer Institute Common Terminology Criteria for Adverse Events（ NCI-CTCAE）

the number of patients with adverse reactions was smaller if they were treated by Shenqi Fuzheng Injection（ 参芪扶正注射液） combined with chemotherapy instead of chemotherapy alone（ P < 0. 05）. The Kushen Injection could ameliorate leukopenia（ P < 0. 05）. Yadanzi Injection（ 鸦胆子注射液） or Zhongjiefeng Injection（ 肿节风注射液） combined with endocrine therapy showed significant difference in reducing the level of prostate specific antigen（ PSA）（ P < 0. 0001）. Meta-analysis showed that Chinese medicine injection combined with endocrine therapy could improve Karnofsky Score 1. 77 times compared with endocrine therapy alone（ RR = 1. 77

95% CI [1. 34

2. 35 ]

I2= 0%

4 studies involved）. Shenqi Fuzheng Injection combined with endocrine therapy could reduce the prostate volume（ PV） more significantly than endocrine therapy alone（ MD =- 5. 73

95% CI [- 7. 44

- 4. 02]

2 studies involved）. Conclusion As an adjuvant therapy

Chinese medicine injection could improve the quality of life of patients with prostate cancer and reduce PSA level

Karnofsky Score

international prostate symptom score（ IPSS）

the level of serum testosterone and PV. It may also reduce the adverse effects. But these evidences are of low-quality till now

and more supportive studies of high-quality are expected.